Ying Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ying Gao has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Yimin He
Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology
3 shared publicationsAiping Deng
Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
1 shared publicationChangchang Li
Department of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Zhejiang University of Traditional Chinese Medicine Wenzhou China
1 shared publicationFei Wu
Department of Dermatopathology, Shanghai Skin Disease Hospital Tongji University School of Medicine Shanghai China
1 shared publicationFeng Cai
Department of Stomatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
1 shared publicationHengfei Li
Department of Infectious Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan
1 shared publication
Latest Publications
- Open Access
- 25 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1826076
A clinical investigation using reflectance confocal microscopy to evaluate the add-on efficacy of the Shumin treatment instrument combined with doxycycline for rosacea
Objective: This study aimed to compare the clinical efficacy and safety of two rosacea treatment regimens: oral doxycycline plus the Shumin treatment instrument and oral doxycycline plus red light therapy. Objective assessments, including reflectance confocal microscopy, were used to evaluate both regimens. Materials and methods: A total of 60 patients with rosacea were randomly divided into two groups, each containing 30 patients. The control group received doxycycline (100 mg/day) orally combined with red light therapy for 12 weeks (twice a week), whereas the experimental group received doxycycline (100 mg/day) orally combined with Shumin treatment instrument therapy for 12 weeks (twice a week). Results: The efficacy rate was 93.3% in the experimental group and 80.0% in the control group. Following treatment, significant reductions in Dermatology Life Quality Index scores and Demodex counts were achieved in both groups (all p < 0.001). However, the experimental group exhibited superior improvements in Dermatology Life Quality Index scores and affected hair follicle counts compared with the control group ( p < 0.05). No significant difference was observed in the reduction in the total Demodex count between the groups. Similarly, no significant difference was observed in the change in the total hair follicle number between the groups. Furthermore, the relapse rate was notably lower in the experimental group than in the control group ( p = 0.026). Conclusion: When used as an adjunctive therapy with oral doxycycline, the Shumin device yields better clinical outcomes than red light therapy for treating rosacea and has a favorable safety profile. These preliminary results establish a basis for the use of adjuvant physical interventions for rosacea.
- 25 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1826076
Open AccessA clinical investigation using reflectance confocal microscopy to evaluate the add-on efficacy of the Shumin treatment instrument combined with doxycycline for rosacea
Objective: This study aimed to compare the clinical efficacy and safety of two rosacea treatment regimens: oral doxycycline plus the Shumin treatment instrument and oral doxycycline plus red light therapy. Objective assessments, including reflectance confocal microscopy, were used to evaluate both regimens. Materials and methods: A total of 60 patients with rosacea were randomly divided into two groups, each containing 30 patients. The control group received doxycycline (100 mg/day) orally combined with red light therapy for 12 weeks (twice a week), whereas the experimental group received doxycycline (100 mg/day) orally combined with Shumin treatment instrument therapy for 12 weeks (twice a week). Results: The efficacy rate was 93.3% in the experimental group and 80.0% in the control group. Following treatment, significant reductions in Dermatology Life Quality Index scores and Demodex counts were achieved in both groups (all p < 0.001). However, the experimental group exhibited superior improvements in Dermatology Life Quality Index scores and affected hair follicle counts compared with the control group ( p < 0.05). No significant difference was observed in the reduction in the total Demodex count between the groups. Similarly, no significant difference was observed in the change in the total hair follicle number between the groups. Furthermore, the relapse rate was notably lower in the experimental group than in the control group ( p = 0.026). Conclusion: When used as an adjunctive therapy with oral doxycycline, the Shumin device yields better clinical outcomes than red light therapy for treating rosacea and has a favorable safety profile. These preliminary results establish a basis for the use of adjuvant physical interventions for rosacea.
- Open Access
- 5 February 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12
A novel variant c.A527G in ITGB4 leads to autosomal dominant epidermolysis bullosa in China
Objective: This study aimed to uncover the genetic variations and their corresponding clinical features in a Chinese family affected by epidermolysis bullosa (EB). Methods: We enrolled a Chinese family clinically diagnosed with EB and conducted whole-exome sequencing on the proband to identify genetic variations. I-TASSER and PyMOL software were used to examine the structural and functional implications of the identified mutant proteins. Results: The study identified an autosomal-dominant form of epidermolysis bullosa simplex (EBS) in the family, attributed to a novel missense variation c.A527G (D176G) in the ITGB4 gene. By bioinformatics analyses, we found that the wild-type D176 forms one hydrogen bond with a distance of 3.1 Å from F201, one hydrogen bond with a distance of 2.7 Å from K177, and two hydrogen bonds with a distance of 3.2 Å from Y304; however, the mutant G176 only forms one hydrogen bond with F201 at a distance of 3.2 Å. Conclusions: This study confirms the dominant mode of inheritance of the missense ITGB4 mutation observed in EB. The novel missense variation c.A527G (D176G) in ITGB4 involves a transition from a polar to non-polar amino acid and a decrease in intermolecular hydrogen bonding, which was associated with EB development.
- 5 February 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12
Open AccessA novel variant c.A527G in ITGB4 leads to autosomal dominant epidermolysis bullosa in China
Objective: This study aimed to uncover the genetic variations and their corresponding clinical features in a Chinese family affected by epidermolysis bullosa (EB). Methods: We enrolled a Chinese family clinically diagnosed with EB and conducted whole-exome sequencing on the proband to identify genetic variations. I-TASSER and PyMOL software were used to examine the structural and functional implications of the identified mutant proteins. Results: The study identified an autosomal-dominant form of epidermolysis bullosa simplex (EBS) in the family, attributed to a novel missense variation c.A527G (D176G) in the ITGB4 gene. By bioinformatics analyses, we found that the wild-type D176 forms one hydrogen bond with a distance of 3.1 Å from F201, one hydrogen bond with a distance of 2.7 Å from K177, and two hydrogen bonds with a distance of 3.2 Å from Y304; however, the mutant G176 only forms one hydrogen bond with F201 at a distance of 3.2 Å. Conclusions: This study confirms the dominant mode of inheritance of the missense ITGB4 mutation observed in EB. The novel missense variation c.A527G (D176G) in ITGB4 involves a transition from a polar to non-polar amino acid and a decrease in intermolecular hydrogen bonding, which was associated with EB development.
- 1 April 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (9) , e296-e297
A case of plasma cell vulvitis successfully treated with crisaborole
- 1 April 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (9) , e296-e297
A case of plasma cell vulvitis successfully treated with crisaborole
- Open Access
- 17 February 2024
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 46, 104005
Successful treatment of refractory oral condyloma acuminatum through laser-photodynamic therapy combination
- 17 February 2024
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 46, 104005
Open AccessSuccessful treatment of refractory oral condyloma acuminatum through laser-photodynamic therapy combination